Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9537043 | 1.00 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL9537041 | 1.00 | CYP1A2 (0.41) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL11143116 | 0.98 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL4043871 | 0.98 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL3775732 | 0.98 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL9301362 | 0.98 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Water SCHEMBL10639693 | 0.98 | CYP1A2 (0.40) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Acetic Acid SCHEMBL9484548 | 0.93 | CYP1A2 (0.37) | CYP1A2ALDH1A1USP2LMNATSHR | |
| Acetic Acid SCHEMBL10419545 | 0.93 | CYP1A2 (0.37) | CYP1A2ALDH1A1USP2LMNATSHR | |
| SCHEMBL9320553 | 0.85 | CYP2C19 (0.33) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7537857-B2 | Reduced degradation of ion-exchange membranes in electrochemical fuel cells | BDF IP HOLDINGS LTD. (CA) | 2009-05-26 | — | — | US | claimed |
| US-6030840-A | CONTACTING CHELATED LANTHANIDE METAL IONS BOUND TO MARKER WITH BUFFERED SOLUTION OF DETERGENT, ENHANCER REAGENT AND POLYANION; IONS DISSOCIATE FROM MARKER AND REASSOCIATE WITH ENHANCER; THEN DETERMINING AMOUNT OF IONS LIBERATED | NEN LIFE SCIENCES, INC. (US) | 2000-02-29 | — | — | US | claimed |
| WO-1999066333-A1 | NEUTRAL ENHANCEMENT OF LANTHANIDES FOR TIME RESOLVED FLUORESCENCE | NEN LIFE SCIENCE PRODUCTS, INC. (US) | 1999-12-23 | — | — | WO | claimed |
| EP-0150844-B1 | METHOD OF RADIOACTIVELY LABELING DIAGNOSTIC AND THERAPEUTIC AGENTS CONTAINING A CHELATING GROUP | ENZO BIOCHEM, INC. (US) | 1993-07-28 | — | — | EP | claimed |
| US-4772548-A | Radioisotopicassay using isotope transfer to chelator-target recognition molecule conjugate | ENZO BIOCHEM, INC. (US) | 1988-09-20 | — | — | US | claimed |
| US-4767609-A | Therapeutic and diagnostic processes using isotope transfer to chelator-target recognition molecule conjugate | ENZO BIOCHEM, INC. (US) | 1988-08-30 | — | — | US | claimed |
| US-4707352-A | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group | ENZO BIOCHEM, INC. (US) | 1987-11-17 | — | — | US | claimed |
| EP-0150844-A2 | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group | ENZO BIOCHEM, INC. (US) | 1985-08-07 | — | — | EP | claimed |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2023-03-28 | — | — | US | disclosed |
| CN-107922454-B | Dual quencher probes | 生物检索技术股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-09-30 | — | — | US | disclosed |
| EP-3883943-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | Technion Research & Development Foundation Limited (IL) | 2021-09-29 | — | — | EP | disclosed |
| US-20210275557-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2021-09-09 | — | — | US | disclosed |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | ELOXX PHARMACEUTICALS LTD. (IL) | 2021-01-26 | — | — | US | disclosed |
| US-4772548-A | Radioisotopicassay using isotope transfer to chelator-target recognition molecule conjugate | ENZO BIOCHEM, INC. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4767609-A | Therapeutic and diagnostic processes using isotope transfer to chelator-target recognition molecule conjugate | ENZO BIOCHEM, INC. (US) | 1988-08-30 | — | — | US | disclosed |
| EP-0258616-A1 | NMR Imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes | SALUTAR, INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4707352-A | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group | ENZO BIOCHEM, INC. (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0150844-A2 | Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group | ENZO BIOCHEM, INC. (US) | 1985-08-07 | — | — | EP | disclosed |
| US-4049585-A | BUILDERS, LOW SUDSING | THE PROCTER & GAMBLE COMPANY (US) | 1977-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275557-A1 | MODIFIED AMINOGLYCOSIDE COMPOUNDS AND USES THEREOF IN DISABLING BACTERIAL RIBOSOME | FBL, MRPL21, NOP2 | CYP1A2 4233/4885ALDH1A1 1534/4885USP2 4503/4885 |
| US-20210300958-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | CYP1A2 2733/4885ALDH1A1 1473/4885USP2 4425/4885 |
| US-11613551-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | CYP1A2 2733/4885ALDH1A1 1473/4885USP2 4425/4885 |
| US-10899785-B2 | Aminoglycoside derivatives and uses thereof in treating genetic disorders | UPF1, AARS1, NUDT21 | CYP1A2 2733/4885ALDH1A1 1473/4885USP2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.